Martin Munchbach
Pureos Bioventures
Zurich
Overview
Work Experience
Managing Partner
2017 - Current
Pureos is a venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats.
Board Member
2019
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience.
Board Member
2021
Board Member
2021
Board Member
2019
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). The company has in-licensed platform technologies and a monoclonal antibody drug candidate which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York
Board Member
2011 - 2022
binx health has the world’s fastest FDA-cleared molecular platform for CT/NG testing. The technology brings rapid, accurate and convenient infectious disease testing to people where they live, work and shop.
Board Member
2005 - 2022
Board Observer
2020 - 2021
Lava Therapeutics B.V. is a biotechnology company, founded in 2016, that creates and develops next generation γδ T cell engaging bispecific antibodies for the treatment of cancer. Our first-in-class immuno-oncology approach activates γδ T cells in a tumor target dependent manner. The objective of Lava Therapeutics B.V is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells.
Senior Investment Manager Private Equity
2004 - 2021
Board Member
2013 - 2019